Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Cannabis Global Inc. (CBGL)
USD0.00
+0.00 (+0.00%)
US OTC Healthcare Drug Manufacturers - Specialty & Generic
Address
520 South Grand Avenue 90071
Los Angeles, CA, US
Los Angeles, CA, US
CEO
Edward F. Manolos
Website
cannabisglobalinc.com
IPO
2008-06-19
CIK 1413488 ISIN US13767G1004
Description
Cannabis Global, Inc. focuses on the creating and commercialization of engineered technologies to deliver hemp extracts and cannabinoids to the human body. The company offers cannabis flower packaged, pre-rolls, and edible products to cannabis retailers and distributors; and Comply Bag, a solution for cannabis storage, transport, and tracking. It also provides managerial services in areas of the regulated hemp and cannabis industries. The company was formerly known as MCTC Holdings, Inc. and changed its name to Cannabis Global, Inc. in December 2019. Cannabis Global, Inc. was incorporated in 2005 and is headquartered in Los Angeles, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
48M
Beta
80.29
Float Shares
538.35M
Free Float %
94.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -50.00% | +9,900.00% | +0.00% | +9,900.00% | +9,900.00% | +0.00% | +100.00% | -80.00% | -99.87% | -99.68% | -93.33% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.00
Quality scores
Altman Z-Score
-49.67
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
4 / 10
Developing
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
3 / 5
Medium
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%—
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+100.0% ★
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%—
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%—
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%— Q3'25: +1.6% (vs Q3'24)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+70.2% Q3'25: +52.0% (vs Q3'24)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-128.03× Q3'25: -159.72× (vs Q3'24)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-87.2K
OE per share TTM
0.00
Owner's Yield
-13.28%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
93.7%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
3
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Global, Inc. EIN 83-1754057 | 650.00M | 10.73% | 650.00M | — | 650.00M | — | CO | NEVADA | 2021-09-08 | ↗ |
| 2 | Tabular Investments, LLC 84-2426877 | 4.15M | 5.50% | 4.15M | — | 4.15M | — | CO | US | 2021-05-18 | ↗ |
| 3 | GHS Investments, LLC | 2.90M | 11.86% | 2.90M | — | 2.90M | — | PN | Nevada | 2020-08-24 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
0
Sells
1
Shares acquired
—
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+0
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2020-10-30 | Riley Jim L. | Director | — | D | Common | 0 | 0.00 | — | 500,000 | — | ↗ |
| 2020-09-30 | GHS Investments, LLC | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-09-10 | GHS Investments, LLC | 10% Owner | S-Sale | D | Common Stock | 45,563 | 0.09 | 4.1K | 3,090,453 | — | ↗ |
| 2020-09-09 | GHS Investments, LLC | 10% Owner | S-Sale | D | Common Stock | 31,297 | 0.11 | 3.4K | 3,136,016 | — | ↗ |
| 2020-09-04 | GHS Investments, LLC | 10% Owner | S-Sale | D | Common Stock | 16,500 | 0.13 | 2.1K | 3,167,313 | — | ↗ |
| 2020-09-03 | GHS Investments, LLC | 10% Owner | S-Sale | D | Common Stock | 11,500 | 0.12 | 1.4K | 3,183,813 | — | ↗ |
| 2020-09-02 | GHS Investments, LLC | 10% Owner | S-Sale | D | Common Stock | 30,117 | 0.13 | 3.8K | 3,195,313 | — | ↗ |
| 2020-08-25 | GHS Investments, LLC | 10% Owner | S-Sale | D | Common Stock | 22,900 | 0.15 | 3.3K | 3,225,430 | — | ↗ |
| 2020-08-24 | GHS Investments, LLC | 10% Owner | S-Sale | D | Common Stock | 18,511 | 0.16 | 2.9K | 3,248,330 | — | ↗ |
| 2020-08-21 | GHS Investments, LLC | 10% Owner | S-Sale | D | Common Stock | 28,679 | 0.16 | 4.6K | 3,266,841 | — | ↗ |
| 2020-08-20 | GHS Investments, LLC | 10% Owner | S-Sale | D | Common Stock | 39,747 | 0.17 | 6.6K | 3,295,520 | — | ↗ |
| 2020-08-19 | GHS Investments, LLC | 10% Owner | S-Sale | D | Common Stock | 25,962 | 0.16 | 4.1K | 3,335,267 | — | ↗ |
| 2020-08-18 | GHS Investments, LLC | 10% Owner | S-Sale | D | Common Stock | 47,992 | 0.17 | 8.1K | 3,361,229 | — | ↗ |
| 2020-08-14 | GHS Investments, LLC | 10% Owner | — | D | Promissory Note | 738,806 | 0.10 | 74.3K | 0 | — | ↗ |
| 2020-08-07 | GHS Investments, LLC | 10% Owner | — | D | Common Shares | 0 | 0.00 | — | 3,409,221 | — | ↗ |
| 2020-06-19 | Tabatabaei Arman | Director / Officer | A-Award | A | Common Stock | 2,500,000 | 0.31 | 774.0K | 3,300,000 | — | ↗ |
| 2019-06-17 | Tabatabaei Arman | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 800,000 | — | ↗ |
| 2019-06-17 | Hymers III R. Leslie | Director / 10% Owner | — | D | Common stock | 0 | 0.00 | — | 43,333,334 | — | ↗ |
| 2019-06-07 | Lauderdale Holdings, LLC | Director / Officer / 10% Owner | S-Sale | D | Common | 130,000,000 | 0.00 | 325.0K | 0 | — | ↗ |
| 2018-05-15 | Lauderdale Holdings, LLC | Director / Officer / 10% Owner | — | D | Common | 0 | 0.00 | — | 130,000,000 | — | ↗ |
| 2008-09-08 | RAYAT HARMEL S | 10% Owner | D-Return | D | COMMON | 36,749,600 | 0.08 | 2.94M | 36,749,600 | — | ↗ |
| 2008-08-05 | PATEL MEETESH V | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2008-08-05 | GAMACHE DAVID A | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
568.21M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Edward Manolos | Chairman, Chief Executive Officer, Chief Financial Officer, Principal Accounting Officer, President, Secretary & Treasurer | — | male |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CBGL
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
